Effect of Nordic Berries on Cognitive Function, Cardiometabolic Risk Markers and Gut Microbiota in Adults With Mild Cognitive Impairment

The study will be conducted with a randomized, double-blind, parallel-group (2 arms) placebo-controlled, single-center interventional design. The aim is to investigate the effects on cognitive function and cardiometabolic risk markers after 12 weeks intake of a berry product vs. a reference product. The reference will be isocaloric and matched in taste, appearance, volume and macronutrient composition to the active berry product.

Two groups, each of 50 volunteers, are studied. Volunteers will be patients attending the Cognitive medicine unit at Ängelholm hospital, who have mild cognitive impairment (but not dementia). One group of volunteers will consume the berry product while the other group act as control and will consume the reference product.

Each volunteer will be seen for a screening visit as well as one pre- and one post-intervention visit at the clinic. In addition, there will be 2 follow-up calls in between visits. Pre- and post-intervention visits will include cognitive assessment with the CANTAB battery (episodic memory and verbal recognition memory), as well as additional cognitive and behavioral tests. Cardiometabolic parameters will be addressed (plasma glucose, insulin, inflammatory markers, blood lipids, body composition) and fecal samples collected.

Inclusion criteria

• Age of 55 years or older.
• Cognitive impairment in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria and global deterioration scale (GDS) stage 3.
• Capable and willing to give written informed consent.
• Capable and willing to perform cognitive testing (mastering the Swedish language, functional vision and hearing or the use of visual or hearing aids during testing).
• Capable and willing to ingest the study beverage for 12 weeks and to follow the instructions given.

Exclusion criteria

• MMSE (Mini-Mental State Examination) <24 (at screening or in the last 3 months).
• Cognitive disease (e.g. dementia) according to Global Deterioration Scale (GDS) stage 4 and up.
• Severe affective disorder with current symptoms
• Severe mental disorder.
• Newly diagnosed or poorly regulated thyroid disease (unstable dose since 3 months back).
• Ongoing insulin therapy.
• Ongoing treatment for malignancy*.
• Conditions with major impact on the gastrointestinal tract (such as Crohn's disease, ulcerative colitis, diagnosed gluten intolerance, undertaken intestinal resection or weight loss surgery).
• Planned major intervention in health care over the next 3 months (the study period).
• Undergoing antibiotic therapy for the last 3 months prior to inclusion in the study.
• Allergy / intolerance to berries or other ingredients in the study products (i.e., colorants, aromas, starch).
• Vegetarians / vegans.
• Smoking.
• Abuse of alcohol or psychoactive substance.
• Significant change in medication over the last 3 months.
• Daily, regular high consumption of berries or juices / marmalade / product with high content of these berries (guideline no more than 5 grams per day). (Can be recruited for the study if this intake ceases before visit 1. High consumes (approximately 1 dl of berries per day) has to cease with this at least one month before visit 1.)
• Taking supplements with potential cognitive effects (e.g. omega-3, ginko biloba), or containing grape and berry extracts or probiotics (capsules or other). (Can be recruited if this intake ceases at least one month before visit 1).
• Planned longer absence/vacation during the next 3 months (the study period).
• Concurrent participation in other clinical intervention trials (dietary/pharmacological).
• Other reasons that make the Study investigator in consultation with the responsible physician deem the person inappropriate to include.

• basalioma exempt from exclusion criteria.